Octreotide · source year
4 selected, source-linked Octreotide records carrying a 2022 source date. This is a navigational view of PeptideScanner’s selected coverage—not a complete research timeline or a statement about safety or effectiveness.
4 selected records.
2 represented types.
4 distinct public records.
Cited chronology
Safety
FDA's dated enforcement report D-0058-2023 lists Class I and source status Terminated for Viatris Inc. PeptideScanner connects the report to reviewed application ANDA079198 through exact openFDA application-number annotations.
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT01229943 at 2026-07-30T19:36:31.409Z. Its registry update date was 2022-08-04, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT02010385 at 2026-07-30T19:39:59.677Z. Its registry update date was 2022-05-23, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT03520569 at 2026-07-30T19:39:59.677Z. Its registry update date was 2022-05-13, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗